Schmitz-Dräger B J, Lümmen G, Schäfer R M
Urologie, EuromedClinic, Europa-Allee 1, 90763 Fürth, Germany.
Urologe A. 2007 Jun;46(6):611-5. doi: 10.1007/s00120-007-1352-3.
Fueled by the results from recently published large interventional trials the topic of chemoprevention of prostate cancer has increasingly attracted the interest of practicing urologists. In this analysis the term"chemoprevention" comprises all agents not included in regular food intake. If possible, the results from interventional studies were considered. Today, it must be accepted as evidence-based that chemoprevention of prostate cancer by 5alpha-reductase inhibition using finasteride is possible. Furthermore, there is increasing evidence that selective estrogen receptor modulators (SERMs) may also have preventive potential. Prospective interventional trials investigating these substances are currently underway. Considering the high incidence and the fact that the diagnosis of prostate cancer has serious impact on the future life of the respective individuals further scientific evaluation of chemoprevention of prostate cancer is mandatory.
近期发表的大型干预试验结果推动下,前列腺癌化学预防这一话题越来越吸引泌尿外科医生的关注。在本分析中,“化学预防”一词包括常规饮食摄入之外的所有药物。如有可能,会考虑干预性研究的结果。如今,必须承认基于证据的观点:使用非那雄胺抑制5α-还原酶进行前列腺癌化学预防是可行的。此外,越来越多的证据表明选择性雌激素受体调节剂(SERMs)也可能具有预防潜力。目前正在进行研究这些物质的前瞻性干预试验。鉴于前列腺癌的高发病率以及其诊断对个体未来生活有严重影响这一事实,对前列腺癌化学预防进行进一步科学评估是必要的。